Beneficient Enters into $1.91 Million GP Primary Capital Transaction
Beneficient (NASDAQ: BENF) has completed a $1.91 million primary capital transaction with Mendoza Ventures Growth Fund III, LP. The deal represents Ben's third GP Primary transaction of the fiscal year and fourth since launching the program in late 2024.
The Fund received Resettable Convertible Preferred Stock convertible into Ben's Class A common stock. The transaction is expected to increase Ben's ExAlt loan portfolio collateral by $1.91 million. Additionally, Ben entered into a Preferred Liquidity Provider Program Agreement with the Fund to facilitate ongoing liquidity solutions.
This initiative is part of Ben's GP Primary Commitment Program, which aims to address up to $330 billion of potential demand for primary commitments in fundraising.
Beneficient (NASDAQ: BENF) ha completato una operazione di capitale primario da 1,91 milioni di dollari con Mendoza Ventures Growth Fund III, LP. L'accordo rappresenta la terza transazione GP Primary di Ben nell'anno fiscale e la quarta da quando il programma è stato lanciato alla fine del 2024.
Il Fondo ha ricevuto azioni privilegiate convertibili resettabili, convertibili in azioni ordinarie di classe A di Ben. Si prevede che la transazione aumenterà il portafoglio di prestiti ExAlt di Ben come garanzia di 1,91 milioni di dollari. Inoltre, Ben ha stipulato un accordo di Preferred Liquidity Provider Program con il Fondo per facilitare soluzioni di liquidità continue.
Questa iniziativa fa parte del Programma di Impegno GP Primary di Ben, che mira a soddisfare una domanda potenziale fino a 330 miliardi di dollari per impegni primari nelle raccolte fondi.
Beneficient (NASDAQ: BENF) ha completado una transacción de capital primario de 1.91 millones de dólares con Mendoza Ventures Growth Fund III, LP. El acuerdo representa la tercera transacción GP Primary de Ben en el año fiscal y la cuarta desde el lanzamiento del programa a finales de 2024.
El Fondo recibió acciones preferentes convertibles reajustables, convertibles en acciones comunes Clase A de Ben. Se espera que la transacción aumente la cartera de préstamos ExAlt de Ben como colateral en 1.91 millones de dólares. Además, Ben firmó un acuerdo del Programa de Proveedores de Liquidez Preferente con el Fondo para facilitar soluciones de liquidez continuas.
Esta iniciativa forma parte del Programa de Compromisos GP Primary de Ben, que busca atender una demanda potencial de hasta 330 mil millones de dólares para compromisos primarios en la recaudación de fondos.
Beneficient (NASDAQ: BENF)는 Mendoza Ventures Growth Fund III, LP와 함께 191만 달러 규모의 1차 자본 거래를 완료했습니다. 이번 거래는 2024년 말 프로그램 시작 이후 Ben의 세 번째 GP Primary 거래이자 올해 회계연도 내 네 번째 거래입니다.
해당 펀드는 Ben의 클래스 A 보통주로 전환 가능한 리셋 가능한 전환 우선주를 받았습니다. 이 거래를 통해 Ben의 ExAlt 대출 포트폴리오 담보가 191만 달러 증가할 것으로 예상됩니다. 또한 Ben은 지속적인 유동성 솔루션을 지원하기 위해 펀드와 우선 유동성 제공자 프로그램 계약을 체결했습니다.
이 이니셔티브는 최대 3,300억 달러의 1차 약정 수요를 충족하는 것을 목표로 하는 Ben의 GP Primary Commitment Program의 일환입니다.
Beneficient (NASDAQ : BENF) a finalisé une transaction de capital primaire de 1,91 million de dollars avec Mendoza Ventures Growth Fund III, LP. Cet accord représente la troisième transaction GP Primary de Ben au cours de l'exercice et la quatrième depuis le lancement du programme fin 2024.
Le Fonds a reçu des actions privilégiées convertibles réinitialisables, convertibles en actions ordinaires de classe A de Ben. La transaction devrait augmenter la garantie du portefeuille de prêts ExAlt de Ben de 1,91 million de dollars. De plus, Ben a conclu un accord dans le cadre du Preferred Liquidity Provider Program avec le Fonds pour faciliter des solutions de liquidité continues.
Cette initiative fait partie du Programme d'Engagement GP Primary de Ben, qui vise à répondre à une demande potentielle pouvant atteindre 330 milliards de dollars pour les engagements primaires lors des levées de fonds.
Beneficient (NASDAQ: BENF) hat eine Primärkapitaltransaktion in Höhe von 1,91 Millionen US-Dollar mit Mendoza Ventures Growth Fund III, LP abgeschlossen. Der Deal stellt die dritte GP-Primary-Transaktion von Ben im Geschäftsjahr und die vierte seit Einführung des Programms Ende 2024 dar.
Der Fonds erhielt zurücksetzbare wandelbare Vorzugsaktien, die in Bens Stammaktien der Klasse A umgewandelt werden können. Die Transaktion wird voraussichtlich Bens ExAlt-Darlehensportfolio als Sicherheiten um 1,91 Millionen US-Dollar erhöhen. Zusätzlich hat Ben eine Vereinbarung zum Preferred Liquidity Provider Program mit dem Fonds abgeschlossen, um fortlaufende Liquiditätslösungen zu ermöglichen.
Diese Initiative ist Teil von Bens GP Primary Commitment Program, das darauf abzielt, eine potenzielle Nachfrage von bis zu 330 Milliarden US-Dollar für Primärzusagen bei der Kapitalbeschaffung zu bedienen.
- Expansion of GP Primary Commitment Program with third transaction of fiscal year
- Increases ExAlt loan portfolio collateral by $1.91 million
- Strategic partnership through Preferred Liquidity Provider Program Agreement
- Addresses large market opportunity of $330 billion in potential primary commitment demand
- Relatively small transaction size of $1.91 million
- Potential dilution from convertible preferred stock issuance
Insights
Beneficient expands its alternative asset strategy with a $1.91M transaction, showing continued execution of its GP Primary program.
Beneficient has closed a
In this transaction, Beneficient provided the Fund with
This represents the second transaction with this specific Fund Manager, suggesting a developing business relationship that could lead to additional deals. The concurrent Preferred Liquidity Provider Program Agreement creates potential for future revenue through ongoing liquidity solutions for the Fund and its limited partners.
Ben's GP Primary Commitment Program addresses a significant market opportunity, targeting what the company identifies as up to
DALLAS, June 24, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced it has closed on the financing of a
The transaction represents Ben’s third GP Primary transaction of the fiscal year and fourth since formally launching the program in late 2024. In exchange for an interest in the Fund, the Fund received approximately
“We are excited to continue recent momentum by completing another GP primary capital transaction, our second transaction with a fund managed by the Fund Manager,” said Beneficient management. “We will continue to pursue additional opportunities that align with our strategic vision and growth objectives.”
Beneficient’s GP Primary Commitment Program is focused on providing primary capital solutions and financing anchor commitments to general partners during their fundraising efforts while immediately deploying capital into our equity. Through the program, Beneficient seeks to help satisfy the up to
About Beneficient
Beneficient (Nasdaq: BENF) – Ben, for short – is on a mission to democratize the global alternative asset investment market by providing traditionally underserved investors − mid-to-high net worth individuals, small-to-midsized institutions and General Partners seeking exit options, anchor commitments and valued-added services for their funds− with solutions that could help them unlock the value in their alternative assets. Ben’s AltQuote® tool provides customers with a range of potential exit options within minutes, while customers can log on to the AltAccess® portal to explore opportunities and receive proposals in a secure online environment.
Its subsidiary, Beneficient Fiduciary Financial, L.L.C., received its charter under the State of Kansas’ Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight by the Office of the State Bank Commissioner.
For more information, visit www.trustben.com or follow us on LinkedIn.
Contacts
Matt Kreps: 214-597-8200, mkreps@darrowir.com
Michael Wetherington: 214-284-1199, mwetherington@darrowir.com
Investor Relations: investors@beneficient.com
Important Information and Where You Can Find It
This press release may be deemed to be solicitation material in respect of a vote of stockholders to approve the issuance of the Company’s Class A common stock upon conversion of the Preferred Stock (the “Transactions”). In connection with the requisite stockholder approval, Ben will file with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement and a definitive proxy statement, which will be sent to the stockholders of Ben, seeking such approvals related to the Transactions.
INVESTORS AND SECURITY HOLDERS OF BEN AND THEIR RESPECTIVE AFFILIATES ARE URGED TO READ, WHEN AVAILABLE, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTIONS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BEN AND THE TRANSACTIONS. Investors and security holders will be able to obtain a free copy of the proxy statement, as well as other relevant documents filed with the SEC containing information about Ben, without charge, at the SEC’s website (http://www.sec.gov). Copies of documents filed with the SEC by Ben can also be obtained, without charge, by directing a request to Investor Relations, Beneficient, 325 North St. Paul Street, Suite 4850, Dallas, Texas 75201, or email investors@beneficient.com.
Participants in the Solicitation of Proxies in Connection with Transactions
Ben and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in respect of the requisite stockholder approvals under the rules of the SEC. Information regarding Ben’s directors and executive officers is available in its annual report on Form 10-K for the fiscal year ended March 31, 2024, which was filed with the SEC on July 9, 2024 and certain current reports on Form 8-K filed by Ben. Other information regarding the participants in the solicitation of proxies with respect to the Transactions and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC. Free copies of these documents, when available, may be obtained as described in the preceding paragraph.
Not an Offer of Securities
The information in this communication is for informational purposes only and shall not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities. The securities that are the subject of the Transactions have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Transactions. The words ”anticipate,” "believe,” ”continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” ”plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected.
Important factors that could cause actual results to differ materially from those expressed in the forward-looking statements include, among others: the ultimate outcome of the Transactions, including obtaining the requisite vote of securityholders, and the risks, uncertainties, and factors set forth under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date they are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable law.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
FAQ
What is the value of Beneficient's (BENF) latest GP Primary capital transaction?
How many GP Primary transactions has BENF completed in fiscal year 2025?
What type of compensation did BENF provide in the Mendoza Ventures transaction?
What is the market opportunity for BENF's GP Primary Commitment Program?
How will this transaction affect BENF's ExAlt loan portfolio?
